Bulgaria-based global pharmaceutical company Huvepharma, which agreed to acquire certain assets from US-based animal health company Zoetis, LLC earlier this week, expects the deal to add key products to its Asian portfolio.

OP Singh, Managing Director, Huvepharma SEA, said it the acquisition will add 12 new products to the company’s current portfolio of 15 products in South-East Asia.

“This acquisition will strengthen the existing portfolio of products in a big way and add around 40 per cent to its current top line of $25 million,” he said, adding that Huvepharma SEA has plans for major expansion and scale-up of operations in the region.

While Huvepharma has Indian operations based in Pune, Zoetis has them in Mumbai.

The deal, valued at around $74 million, is expected to be completed by the end of January. It includes products and manufacturing sites — two owned and one leased — in the US. The products cover an international portfolio of medicated feed additives including Albac (excluding the US market) and bio-Cox / Salinomax as well as Inovocox, a leading coccidiosis vaccine for broilers. The US manufacturing sites are in Laurinburg, North Carolina and Van Buren, Arkansas.

Other assets included in the acquisition are water soluble veterinary products brands R-Pen, Oxytet, Sul-Q-Nox, CTC, Lincomycin, Poultry Sulfa and Neo-Sol including the formulation facility located in Longmont, Colorado. Employees at the three manufacturing sites will be transferred to the company.

The acquired products are expected to be available from Huvepharma from February, may continue to be ordered from Zoetis prior to that, the company said.

Huvepharma is a privately owned, global animal health company with headquarters in Sofia that brands a broad portfolio of products used in swine, poultry and cattle production. It sells in more than 90 countries with subsidiaries in all major farm animal producing regions including manufacturing sites in Europe and the US.

comment COMMENT NOW